928株革兰阴性杆菌耐药性监测

目的：了解青岛地区临床分离的重要革兰阴性杆菌的耐药情况以指导合理用药。方法：2001年青岛3家医院临床分离的5种革兰阴性杆菌用Kirby-Bauer法进行药敏试验。结果：5种病原菌均占3家医院革兰阴性杆菌分离率的前5位，大肠埃希菌对氟喹诺酮类药物的耐药率达60％－87％，细菌对亚胺培南均呈高度敏感，但铜绿假单胞菌耐亚胺培南株占25．8％，头孢他啶的抗菌活性是三代头孢菌素中最高的；复方酶抑制剂表现出良好的抗菌活性。结论：细菌耐药问题仍是目前临床的严重问题，地域性的耐药性监测是必要的。     

常用消毒剂及自来水对弓形虫速殖子活力的影响

目的了解常用消毒剂及自来水对弓形虫速殖子活力的影响。方法将各种消毒剂分别加入等体积含弓形虫速殖子的小鼠腹水中，在不同时间内观察虫体胎盘蓝（trypanblue）着色率及活动率，并将经消毒剂处理不同时间的速殖予接种昆明鼠，观察速殖子能否在接种鼠体内复苏繁殖，导致小鼠死亡。用类似方法观察自来水时速殖子的影响。结果除甲醛个速殖子在常用浓度的不同消毒剂中，lmin月台盘蓝着色率均为100％，活动率为0。经消毒剂处理1min的速殖子接种小鼠后，各组接种鼠（包括甲醛处理组）无一死亡。经自来水处理4h的速殖子接种小鼠后仍能在小鼠体内复苏繁殖，小鼠于接种1wk内全部死亡。结论弓形虫速殖子对常用消毒剂均很敏感；而在自来水中途殖子可保持感染力4h以上。     

放射性肝纤维化过程的定量研究

经＾６０Ｃｏγ线照射大鼠肝区，通过光镜、电镜和图像分析仪、宣研究了照后１年肝脏的病理改变。结果表明，３０Ｇｙ组在照射后１年内逐渐发生了放射性肝纤维化病变。在肝纤维化发生过程中，肝细胞内糖原颗凿含量进行性减少，间质中胶原纤维含量进行性增加，网状纤维于照射１－３个月呈进行性增加。     

80例健康青年分别经针刺或艾灸肺俞穴后的肺功能变化

目的：探讨针刺与艾灸肺俞穴对健康人肺功能的影响。方法：我们选择了20－22岁健康男性80例，随机分为针刺组和艾灸组各40例，于针刺，艾灸前和针刺，艾灸后10min测试用力肺活量（FVC），用力呼气量（FEV1．0），最大呼气中段流速（MMF），最大呼气流量（PEFR），75％，50％，25％肺活量时的最大呼气流速（V75，V50，V25），结果：显示经针刺和艾灸肺俞穴后2组FVC，FFV1．0均显著增加，P＜0．05，2组间比较针刺组FVC明显高于艾灸组，P＜0．05，而且艾灸组MMF，V25亦显著降低P＜0．05，结论：健康人经针刺和艾灸肺俞穴后均可使大气道阻力减少，肺容量增加，提示一定量的艾燃烧后的烟雾可使健康人肺功能受到影响，使肺的小气道收缩，出现阻塞性改变。     

肾上腺素能β1受体亚型特异性抗体的制备及鉴定

【目的】制备和鉴定 β1受体亚型特异性抗体。【方法】人工合成 β1受体细胞膜外第二环 197 2 2 2位氨基酸序列作为抗原。连接钥孔冒贝血蓝蛋白 (KLH)增加抗原性后免疫兔获得抗血清。通过凝胶双扩散实验和ELISA法鉴定其效价 ;通过免疫荧光法及ELISA法鉴定其特异性 ;通过离体蛙心灌流实验鉴定其药理活性。【结果】该抗血清效价高 (分别为 1∶6 4和 1∶10 6)、特异性强 ,能和心肌 β1受体发生特异性结合 (1∶10 4 ～ 1∶10 5) ,为异丙肾上腺素的非竞争性拮抗剂。 (pD2 ′ =1 6 2 )。【结论】成功制备的 β1受体亚型特异性抗体可能成为进一步研究 β1受体分布、功能和定量的有力工具。     

基底节区脑出血改良术式病人的术后护理

基底节区脑出血的手术治疗已广泛开展,但由于手术创伤较大,并发症较多.为了减少手术创伤,现采用改良翼点入路手术,以减少手术对大脑皮层的损伤.本文对改良术式与传统术式病人术后临床观察比较及护理进行了探讨,以期在一定程度上对此类病人的术后护理有所帮助.     

坏宜性脓皮病12例临床分析

报告12例疸性腔皮病患者的性别与年龄构成、并发症、实验室检查、治疗经过和结果，对该病的病因、治疗和预后进行了讨论。     

鼻内窥镜下鼻中隔矫正术

目的 :研究鼻内窥镜下鼻中隔矫正术的优点。方法 :鼻内窥镜下鼻中隔矫正术 5 0例 ,同期施行传统的鼻中隔矫正术 5 0例作为对照 ,分析两者手术时间、术中出血量及疼痛情况。结果 :鼻内窥镜组治愈率为96% ,手术时间 ( 35 .5 0± 5 .2 0 ) min,术中出血量 ( 2 3.2 2± 4.2 5 ) ml,疼痛发生率为 1 6% ;传统手术组治愈率为 90 % ,手术时间 ( 4 5 .64± 6.34) min,术中出血量 ( 31 .34± 5 .64) ml,疼痛发生率为 38%。经统计学分析两组治愈率差异无显著性 ( P>0 .0 5 ) ,鼻内窥镜组手术时间明显缩短 ( P<0 .0 1 ) ,术中出血量明显减少 ( P<0 .0 5 ) ,术中疼痛发生率明显降低 ( P<0 .0 5 )。结论 :鼻内窥镜下鼻中隔矫正术照明好 ,术野清晰 ,直视下手术 ,易剥离粘连处和及时发现粘膜损伤 ,手术时间短 ,术中出血量少 ,疼痛轻 ,术后并发症少 ,特别是鼻中隔矫正同期完成功能性鼻内窥镜手术及歪鼻矫正手术时更显示其优越性     

保留肾单位手术治疗早期小肾癌21例临床分析

OBJECTIVE: To evaluate the clinical effects of nephron-sparing surgery in patients with early-stage small renal cell carcinoma. METHODS: Nephron-sparing surgery was performed in 21 patients with renal cell carcinoma including 1 with solitary kidney, 3 with unilateral tumor and contralateral renal compromise, and 17 with unilateral tumor and normal contralateral kidney. The diameter of the tumors ranged from 1.5 to 6.0 cm, with a mean of 2.8 cm. The tumor diameter in 17 patients with normal contralateral kidney was less than 4 cm (mean 2.5 cm) and the average diameter in 4 patients with contralateral renal compromise was 4.2 cm. Sixteen cases were in stage T(1), 4 in stage T(2), and 1 in stage T(3). Of the 21 patients, 4 underwent tumor enucleation, 10 polar nephrectomy and 7 wedge resection. RESULTS: All patients were followed up for an average of 40.8 months (7 to 66 months). One patient suffered a right lung and mediastinum metastasis 3 years after the surgery later and 1 with chronic glomerulonephritis required dialysis 27 months after the operation. No surgical complication or local recurrence were found in other patients. CONCLUSION: As a safe and effective therapy for early-stage small renal cell carcinoma, nephron-sparing surgery can be considered as the gold-standard therapy for patients with lesions less than 4 cm in T(1) and T(2) stages of localized unilateral tumor with normal contralateral kidney.     

放射线联合p53基因及内皮抑素治疗小鼠前列腺癌皮下移植瘤

Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rh-endostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1 × 1010 vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo (P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P < 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 0.05) and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P < 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest (P < 0.05). An increased expression of MVD compared with the control was shown, and MVD in groups C, D and E were always higher than that in the control (P < 0.05). Conclusions The limitation of radiotherapy could be overcome by combination with beth p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and endostatin have their own role but they can be interacted with each other.